BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 30340786)

  • 1. Different Methods of Delivering CRISPR/Cas9 Into Cells.
    Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
    Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
    Wang P
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
    [No Abstract]   [Full Text] [Related]  

  • 4. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
    Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
    Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-mediated genome editing in sea urchins.
    Lin CY; Oulhen N; Wessel G; Su YH
    Methods Cell Biol; 2019; 151():305-321. PubMed ID: 30948015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups.
    Song M
    Biotechnol Prog; 2017 Jul; 33(4):1035-1045. PubMed ID: 28440027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in CRISPR/Cas9 Delivery Strategies.
    Yip BH
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
    Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
    Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
    Li L; Hu S; Chen X
    Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromatin accessibility and guide sequence secondary structure affect CRISPR-Cas9 gene editing efficiency.
    Jensen KT; Fløe L; Petersen TS; Huang J; Xu F; Bolund L; Luo Y; Lin L
    FEBS Lett; 2017 Jul; 591(13):1892-1901. PubMed ID: 28580607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome Editing by CRISPR/Cas9 in Sorghum Through Biolistic Bombardment.
    Liu G; Li J; Godwin ID
    Methods Mol Biol; 2019; 1931():169-183. PubMed ID: 30652290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms.
    Farboud B; Jarvis E; Roth TL; Shin J; Corn JE; Marson A; Meyer BJ; Patel NH; Hochstrasser ML
    J Vis Exp; 2018 May; (135):. PubMed ID: 29889198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome editing in potato via CRISPR-Cas9 ribonucleoprotein delivery.
    Andersson M; Turesson H; Olsson N; Fält AS; Ohlsson P; Gonzalez MN; Samuelsson M; Hofvander P
    Physiol Plant; 2018 Dec; 164(4):378-384. PubMed ID: 29572864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9.
    He ZY; Zhang YG; Yang YH; Ma CC; Wang P; Du W; Li L; Xiang R; Song XR; Zhao X; Yao SH; Wei YQ
    Hum Gene Ther; 2018 Feb; 29(2):223-233. PubMed ID: 29338433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.